ALPS Medical Breakthroughs ETF (SBIO) Covered Calls

The ALPS Medical Breakthroughs ETF is an exchange-traded fund that targets small- and mid-cap biotechnology and pharmaceutical companies. The fund focuses on firms with at least one drug candidate in Phase II or Phase III FDA clinical trials, ensuring exposure to late-stage medical innovation. By requiring a minimum cash runway for its holdings, the ETF seeks to mitigate the financial risks associated with the intensive research and development cycles inherent in the biotech industry.

You can sell covered calls on ALPS Medical Breakthroughs ETF to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for SBIO (prices last updated Wed 3:40 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

The ALPS Medical Breakthroughs ETF (SBIO) provides targeted exposure to the innovative core of the healthcare sector. Unlike broad biotech funds, SBIO specifically selects US-listed companies that have progressed beyond early-stage research into mid-to-late-stage clinical trials. This strategy captures companies at a pivotal stage of their lifecycle, where clinical data readouts can serve as significant catalysts for valuation changes.

To qualify for inclusion, companies must have a market capitalization between $200 million and $5 billion at the time of quarterly rebalancing. A critical safety feature of the fund is its "cash burn" requirement, which mandates that every constituent must have enough cash on hand to sustain operations for at least 24 months. This filter helps protect investors from the frequent dilutive secondary offerings common among cash-strapped biotechnology firms.

Competitive Landscape

SBIO operates within a niche of the biotechnology investment space, competing with both broad sector benchmarks and other specialized thematic funds. Its unique focus on late-stage clinical trials and balance sheet strength distinguishes it from larger, market-cap-weighted indices that are often dominated by mature pharmaceutical giants.

Key competitors and alternative investment vehicles in the biotech and healthcare ETF space include:

1. SPDR S&P Biotech ETF: An equal-weighted fund that provides broad exposure to the biotechnology segment, including many small-cap firms.
2. iShares Biotechnology ETF: A major industry benchmark that tracks a market-cap-weighted index of biotechnology companies.
3. ARK Genomic Revolution ETF: An actively managed fund focusing on companies that benefit from advancements in genomics and molecular diagnostics.
4. Health Care Select Sector SPDR Fund: A broad-based fund that includes large pharmaceutical, medical device, and healthcare provider companies.

Strategic Outlook and Innovation

The fund is designed to capitalize on the increasing pace of biomedical innovation. As the FDA continues to streamline approval pathways for breakthrough therapies, companies in Phase II and III trials are positioned to benefit from potential accelerated approvals. The fund’s focus on the "breakthrough" segment allows it to participate in the growth of companies developing novel treatments for oncology, rare genetic disorders, and chronic metabolic diseases.

The methodology behind the fund is essentially evergreen, as it systematically refreshes its holdings to include the next generation of clinical leaders. By maintaining an equal-weighting strategy, the fund ensures that the success of a single mid-cap company can have a meaningful impact on the overall portfolio performance. This approach provides a diversified way to invest in the high-risk, high-reward nature of pharmaceutical development without the binary risk of owning just one stock.

Want more examples? SBH Covered Calls | SBIT Covered Calls